130,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 130,037 shares of the company’s stock, valued at approximately $2,861,000.

Separately, JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the 4th quarter valued at $45,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares of the company’s stock, valued at $28,778,925. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 34.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MNPR. Piper Sandler reaffirmed an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Monopar Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Monopar Therapeutics Trading Down 13.3 %

Monopar Therapeutics stock opened at $30.00 on Monday. The firm has a market cap of $183.39 million, a PE ratio of -15.23 and a beta of 1.01. The stock’s 50 day simple moving average is $38.29 and its two-hundred day simple moving average is $25.18. Monopar Therapeutics Inc. has a 12 month low of $1.72 and a 12 month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). On average, equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.